Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative evaluation of intravenous daptomycin versus standard-of-care antibiotics in pediatric Staphylococcus aureus bacteremia
2012-003447-29Phase 4Completed
- Sponsor
- Cubist Pharmaceuticals, Inc.
- Start
- Feb 2013
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of daptomycin in Staphylococcal bacteremia, sponsored by Cubist Pharmaceuticals, Inc.. Started Feb 2013; status: completed.
02
Drugs
daptomycin
03
Conditions
Staphylococcal bacteremia
Beyond the preview
Go deeper on 2012-003447-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003447-29.